Quadrant Capital Group LLC Has $510,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Quadrant Capital Group LLC lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,966 shares of the medical device company’s stock after selling 131 shares during the period. Quadrant Capital Group LLC’s holdings in DexCom were worth $510,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Gravity Asset Management Inc. acquired a new stake in shares of DexCom in the 2nd quarter valued at $1,029,000. KB Financial Partners LLC bought a new position in shares of DexCom in the first quarter valued at about $72,000. Avalon Trust Co bought a new position in shares of DexCom in the first quarter valued at about $26,000. TFC Financial Management Inc. raised its holdings in shares of DexCom by 4,814.3% in the first quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock valued at $40,000 after buying an additional 337 shares during the last quarter. Finally, Valley National Advisers Inc. raised its holdings in shares of DexCom by 33.5% in the second quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock valued at $49,000 after buying an additional 95 shares during the last quarter. Institutional investors and hedge funds own 93.88% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on DXCM. Robert W. Baird cut their price target on DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a report on Monday, August 21st. Stifel Nicolaus cut their price target on DexCom from $155.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday, October 10th. Canaccord Genuity Group boosted their price objective on DexCom from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Raymond James dropped their price objective on DexCom from $154.00 to $131.00 and set a “strong-buy” rating for the company in a report on Friday, September 15th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of DexCom in a report on Monday, October 16th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.93.

DexCom Price Performance

DexCom stock opened at $104.97 on Friday. The firm has a market capitalization of $40.56 billion, a P/E ratio of 115.35, a PEG ratio of 2.13 and a beta of 1.13. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $139.55. The business has a 50-day moving average of $91.03 and a 200-day moving average of $109.88. The company has a current ratio of 2.80, a quick ratio of 2.50 and a debt-to-equity ratio of 1.07.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 26th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.16. The company had revenue of $975.00 million during the quarter, compared to analyst estimates of $939.64 million. DexCom had a return on equity of 25.05% and a net margin of 11.08%. The company’s revenue for the quarter was up 26.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 EPS. On average, equities analysts anticipate that DexCom, Inc. will post 1.43 EPS for the current year.

Insider Buying and Selling

In other news, Director Steven R. Altman sold 1,000 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $77.58, for a total transaction of $77,580.00. Following the completion of the transaction, the director now directly owns 60,700 shares of the company’s stock, valued at $4,709,106. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Steven R. Altman sold 1,000 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $77.58, for a total transaction of $77,580.00. Following the completion of the transaction, the director now owns 60,700 shares in the company, valued at $4,709,106. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Barry J. Regan sold 2,019 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total transaction of $192,249.18. Following the transaction, the executive vice president now owns 64,250 shares of the company’s stock, valued at $6,117,885. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,752 shares of company stock valued at $850,297. Company insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.